Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Phase III Trial With Letrozole Alone or in Combination With Zoledronic Acid as Extended Adjuvant Treatment of Postmenopausal Patients With Primary Breast Cancer

NCT00332709 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT00332709
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00332709 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Phase III Trial With Letrozole Alone or in Combination With Zoledronic Acid as Extended Adjuvant Treatment of Postmenopausal Patients With Primary Breast Cancer
Lead sponsor
Novartis
Phase
Phase 3
Overall status
Completed
Start date
January 31, 2006
Completion date
August 31, 2010
Enrollment
83 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

osteoporosis, postmenopausal